112% H1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic Leaders

HENDERSON, Nev., Aug. 26, 2026 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today provides a comprehensive corporate update summarizing the significant clinical and commercial progress achieved during the first half of 2026.

Key Highlights:

  • Sepsis & NETosis Validation: Peer-reviewed paper and independent Editorial published demonstrating that Nu.Q® NETs is an independent predictor of 28-day mortality and the need for renal (kidney) replacement therapy (RRT) in sepsis and septic shock patients. $7.3 million government-backed DETECSEPS program in France due to start recruitment in September 2026.
  • Demonstrates Clinical Utility of Breakthrough Finger-Prick Detection of Nucleosomes: Expanding global market potential for sepsis testing using lateral flow, thereby potentially greatly expanding the addressable market and utility.
  • European Lung Cancer Reimbursement: Plans formal conditional reimbursement submission in France by the end of 2026 to enable routine clinical use.
  • First Half Revenue Growth: Reported $1.4M of revenue in the first half of 2026, representing a 112% increase year-over-year.
  • Feline Lymphoma Manuscript Submission: Submitted for publication the clinical manuscript for the Nu.Q® Vet cancer test in cats; $5 million milestone payment anticipated subsequent to publication.
  • Global Licensing Momentum: Confirms active discussions with more than a dozen of the world's leading diagnostic and liquid biopsy companies, including for technical evaluations.
  • Newly Announced Collaboration: successfully transferred Volition Nu.Q® NETs assay onto Sysmex Corporation's platform, in preparation for anticipated broader agreement. Sysmex Corporation is a multi-billion dollar market capitalization company listed on the Tokyo Stock Exchange.
  • Capture-Seq™ Platform: Peer-reviewed paper published: validation cohort detected over 95% of Stage I and II cancers, Underscores a $23 billion annualized opportunity in cancer detection.